The metabolic articles on this site are mostly about type 2 diabetes, insulin resistance and obesity, which is where the bulk of the TUDCA literature sits. Type 1 diabetes is a different disease with a different problem at its centre. In type 1, the insulin-producing beta cells of the pancreas are destroyed, and the deficit is insulin supply rather than insulin sensitivity.
That makes the beta cell itself the target, and beta cells happen to be unusually vulnerable to endoplasmic reticulum stress, which is TUDCA’s best-characterised mechanism. The research that follows is genuinely interesting. It is also entirely in rodents, and type 1 diabetes is a condition where getting this wrong is dangerous. Nothing here is medical advice, and nobody should alter insulin on the basis of it.
Key Takeaways
- Beta cells manufacture and fold enormous quantities of insulin, which makes the endoplasmic reticulum a natural stress point and a plausible TUDCA target.
- In mice with early-stage streptozotocin-induced type 1 diabetes, TUDCA at 300 mg/kg cut blood glucose by 43% versus untreated diabetic mice after 15 days [1].
- The improvement came from higher circulating insulin, driven partly by increased beta-cell mass and partly by reduced insulin clearance through lower hepatic IDE activity [1]. Insulin sensitivity did not change [1].
- TUDCA acts on beta cells through identified receptors: TGR5, sphingosine-1-phosphate receptor 2 (S1PR2) and α5β1 integrin [2].
- In the same mouse model, early TUDCA treatment preserved visual and retinal function, and treating later worked less well than treating early [3].
- There are no human trials of TUDCA in type 1 diabetes. Type 1 is insulin-dependent and life-threatening if undertreated.
Why the Beta Cell Is an ER Stress Story
A beta cell’s job is to synthesise, fold and secrete insulin on demand, in quantity. Protein folding happens in the endoplasmic reticulum, and a cell running a high-volume protein production line operates close to the limits of its folding capacity as a matter of routine. When demand rises or conditions deteriorate, misfolded protein accumulates and the cell activates the unfolded protein response. Sustained activation of that response pushes cells toward death.
This is why beta cells keep appearing in the ER stress literature. It is also why TUDCA, which acts as a chemical chaperone assisting protein folding and dampening that stress response, has been tested on them repeatedly.
The Early-Stage Type 1 Study
The most directly relevant experiment used C57BL/6 mice given streptozotocin at 40 mg/kg for five days to destroy beta cells. Once diabetes was confirmed, the mice received either TUDCA at 300 mg/kg or phosphate-buffered saline for 24 days [1].
After 15 days of treatment, the TUDCA-treated diabetic mice showed a 43% reduction in blood glucose compared with the untreated diabetic group [1]. In a model where beta cells have been chemically destroyed, that is a large effect.
The Mechanism Has Two Halves, and One of Them Is Easy to Miss
The glucose improvement was driven by higher circulating insulin. The interesting question is where that extra insulin came from, and the answer is not only “the pancreas made more.”
Part of it was indeed beta-cell recovery: the treated mice showed increased beta-cell mass and a higher number of beta cells per islet [1]. That is the headline result and the one most likely to be quoted.
The other part was a reduction in hepatic insulin-degrading enzyme activity, which lowered insulin clearance [1]. In plain terms, some of the extra insulin in circulation was there because less of it was being broken down, not because more was being produced. That is a pharmacokinetic effect on insulin handling rather than a repair of the underlying disease, and it is worth separating from the beta-cell mass finding when judging what the result means.
One further detail sharpens the interpretation: insulin sensitivity was unchanged between groups [1]. The effect was specific to insulin availability, not to how well tissues responded to it. That is consistent with a type 1 rather than type 2 mechanism, and it is a point in the study’s favour.
Which Receptors Are Involved
A review of TUDCA’s actions on pancreatic beta cells identifies three receptors as the focus of the mechanistic work: the G protein-coupled bile acid receptor TGR5, sphingosine-1-phosphate receptor 2 (S1PR2), and α5β1 integrin [2]. The same review is candid that there are relatively few studies explaining the molecular mechanisms behind TUDCA’s effects on beta cells [2], which is a fair description of the field.
S1PR2 shows up again in more recent work on the other pancreatic cell type. TUDCA suppressed glucagon secretion from mouse pancreatic islets and from glucagon-releasing cells, an effect blocked by inhibiting S1PR2 or the PI3K pathway, and accompanied by increased activity of ATP-sensitive potassium channels in alpha cells [4]. Glucagon raises blood glucose, and excess glucagon contributes to hyperglycaemia, so suppressing it is a second, independent route by which the compound could move glucose numbers. That study was framed around type 2 diabetes, but the cell biology is not type-specific.
The Retinal Result, and Why Timing Mattered
Diabetic retinopathy is one of the complications that makes diabetes a whole-body disease. In the same streptozotocin mouse model of type 1 diabetes, animals were treated with vehicle or TUDCA beginning either one week or three weeks after diabetes was induced, then followed with visual and retinal function testing [3].
Diabetic mice showed reduced spatial frequency and contrast sensitivity thresholds compared with controls, along with reduced electroretinogram amplitudes and delayed implicit times [3]. Diabetic mice treated early with TUDCA held their visual function at all timepoints, and the electroretinogram deficits were ameliorated [3].
The finding that carries the most information is the comparison between arms: late treatment showed reduced preservation compared with early treatment [3]. A protective effect that shrinks the longer you wait is what you would expect from a compound preventing damage rather than reversing it, and it is a more informative result than the simple treated-versus-untreated difference.
The Gap Between This and a Person With Type 1 Diabetes
Three things separate these results from any clinical claim.
The model is chemical, not autoimmune. Streptozotocin destroys beta cells directly with a toxin. Human type 1 diabetes is an autoimmune disease in which the immune system progressively attacks the beta cells and keeps attacking them. A treatment that helps surviving beta cells recover from a one-time chemical insult is not automatically a treatment for an ongoing immune assault.
The dose is high. 300 mg/kg in a mouse does not translate milligram-for-milligram to a person. Using the standard body-surface-area conversion, it corresponds very roughly to something in the region of 1.5 to 2 g/day for an adult, which is above most retail label directions. Allometric conversions are estimates, not prescriptions, and they are no substitute for a human dose-finding study.
There is no human trial. Not a small one, not an open-label one. The type 1 evidence is rodent evidence.
The last point matters more here than in most of the topics on this site, because type 1 diabetes is not a condition where an experiment is cheap. Insulin is not optional, hyperglycaemia and diabetic ketoacidosis are medical emergencies, and anything that influences insulin requirements needs to happen with a clinician and a glucose meter, not on the strength of a mouse study.
Frequently Asked Questions
Can TUDCA regenerate beta cells?
In mice with chemically induced diabetes, TUDCA treatment increased beta-cell mass and beta cells per islet [1]. That is a real finding in a rodent model. It has not been shown in humans, and the human disease has an ongoing autoimmune component the mouse model does not reproduce.
Why does insulin-degrading enzyme come up?
Because part of the glucose improvement in the mouse study came from reduced hepatic IDE activity lowering insulin clearance, not from increased insulin production [1]. It is a meaningful distinction: less insulin removed is not the same as more insulin made.
Is there any human evidence in type 1 diabetes?
No trials in type 1 diabetes. The human TUDCA trial evidence sits in other conditions entirely, such as liver disease and progressive multiple sclerosis.
Could TUDCA reduce my insulin needs?
There is no human evidence to support that, and acting on the rodent data would mean experimenting with insulin dosing based on mouse studies. Any change to an insulin regimen belongs with the endocrinologist or diabetes team managing it.
References
- The Bile Acid TUDCA Improves Beta-Cell Mass and Reduces Insulin Degradation in Mice With Early-Stage of Type-1 Diabetes. Frontiers in Physiology (2019).
- TUDCA receptors and their role on pancreatic beta cells. Progress in Biophysics and Molecular Biology (2021).
- Tauroursodeoxycholic Acid Protects Retinal and Visual Function in a Mouse Model of Type 1 Diabetes. Pharmaceutics (2021).
- Inhibition of glucagon secretion from pancreatic α-cells by the bile acid TUDCA involves a S1PR2-PI3K pathway. The Journal of Nutritional Biochemistry (2025).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
